Guggenheim Capital’s Esperion Therapeutics ESPR Stock Holding History

Guggenheim Capital’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-46,985	Closed	-$2.08M	–	2224
2018 Q3	$2.08M	Sell	46,985 -76	-0.2%	-$3.49K	0.01%	1219
2018 Q2	$1.84M	Buy	47,061 +11,547	+33%	+$583K	0.01%	1299
2018 Q1	$2.57M	Sell	35,514 -4,014	-10%	-$295K	0.01%	1454
2017 Q4	$2.6M	Sell	39,528 -15,567	-28%	-$838K	0.01%	1467
2017 Q3	$2.76M	Buy	55,095 +3,428	+7%	+$165K	0.01%	1439
2017 Q2	$2.39M	Buy	+51,667	New	+$1.9M	0.01%	1506
2015 Q4	–	Sell	-8,496	Closed	-$200K	–	3012
2015 Q3	$200K	Sell	8,496 -30,993	-78%	-$1.95M	﹤0.01%	2735
2015 Q2	$3.23M	Buy	+39,489	New	+$3.87M	0.01%	1406

Other funds holding ESPR

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Guggenheim Capital's ESPR Position: Q4 2018 in Review

Guggenheim Capital sold out of Esperion Therapeutics (ESPR) in Q4 2018, closing a stake of 46,985 shares — an estimated $2.08M sold.

Guggenheim Capital first reported a position in ESPR in Q2 2015 and held it in 8 quarters. The position peaked at $3.23M in Q2 2015. 156 funds tracked by Wall St. Rank hold ESPR as of Q4 2018.

Guggenheim Capital reported no remaining Esperion Therapeutics position as of Q4 2018 after selling out during the quarter.
Guggenheim Capital sold 46,985 Esperion Therapeutics shares in Q4 2018, an estimated $2.08M.
Guggenheim Capital first reported a position in Esperion Therapeutics in Q2 2015 and held it in 8 quarters.
Guggenheim Capital's Esperion Therapeutics position peaked at $3.23M in Q2 2015.
156 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2018.

Based on Guggenheim Capital's 13F filing for Q4 2018, filed 14 Feb 2019.